175 related articles for article (PubMed ID: 31080824)
1. Clinical Significance of Plasma Apolipoprotein-AII Isoforms as a Marker of Pancreatic Exocrine Disorder for Patients with Pancreatic Adenocarcinoma Undergoing Chemoradiotherapy, Paying Attention to Pancreatic Morphological Changes.
Hayasaki A; Murata Y; Usui M; Hibi T; Fujii T; Iizawa Y; Kato H; Tanemura A; Azumi Y; Kuriyama N; Kishiwada M; Mizuno S; Sakurai H; Uchida K; Isaji S
Biomed Res Int; 2019; 2019():5738614. PubMed ID: 31080824
[TBL] [Abstract][Full Text] [Related]
2. Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms.
Honda K; Kobayashi M; Okusaka T; Rinaudo JA; Huang Y; Marsh T; Sanada M; Sasajima Y; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Miura N; Kamita M; Sakamoto T; Shoji H; Jung G; Srivastava S; Yamada T
Sci Rep; 2015 Nov; 5():15921. PubMed ID: 26549697
[TBL] [Abstract][Full Text] [Related]
3. CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation.
Honda K; Katzke VA; Hüsing A; Okaya S; Shoji H; Onidani K; Olsen A; Tjønneland A; Overvad K; Weiderpass E; Vineis P; Muller D; Tsilidis K; Palli D; Pala V; Tumino R; Naccarati A; Panico S; Aleksandrova K; Boeing H; Bueno-de-Mesquita HB; Peeters PH; Trichopoulou A; Lagiou P; Khaw KT; Wareham N; Travis RC; Merino S; Duell EJ; Rodríguez-Barranco M; Chirlaque MD; Barricarte A; Rebours V; Boutron-Ruault MC; Romana Mancini F; Brennan P; Scelo G; Manjer J; Sund M; Öhlund D; Canzian F; Kaaks R
Int J Cancer; 2019 Apr; 144(8):1877-1887. PubMed ID: 30259989
[TBL] [Abstract][Full Text] [Related]
4. Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer.
Kashiro A; Kobayashi M; Oh T; Miyamoto M; Atsumi J; Nagashima K; Takeuchi K; Nara S; Hijioka S; Morizane C; Kikuchi S; Kato S; Kato K; Ochiai H; Obata D; Shizume Y; Konishi H; Nomura Y; Matsuyama K; Xie C; Wong C; Huang Y; Jung G; Srivastava S; Kutsumi H; Honda K
J Gastroenterol; 2024 Mar; 59(3):263-278. PubMed ID: 38261000
[TBL] [Abstract][Full Text] [Related]
5. ITRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma.
Lin C; Wu WC; Zhao GC; Wang DS; Lou WH; Jin DY
Medicine (Baltimore); 2016 Aug; 95(31):e4527. PubMed ID: 27495108
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
7. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
8. Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.
Dittmar RL; Liu S; Tai MC; Rajapakshe K; Huang Y; Longton G; DeCapite C; Hurd MW; Paris PL; Kirkwood KS; Coarfa C; Maitra A; Brand RE; Killary AM; Sen S
Cancer Prev Res (Phila); 2021 Jul; 14(7):729-740. PubMed ID: 33893071
[TBL] [Abstract][Full Text] [Related]
9. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
10. The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy with combined resection of portal vein following preoperative chemoradiotherapy.
Jaseanchiun W; Kato H; Hayasaki A; Fujii T; Iizawa Y; Tanemura A; Murata Y; Azumi Y; Kuriyama N; Kishiwada M; Mizuno S; Usui M; Sakurai H; Isaji S
Pancreatology; 2019 Mar; 19(2):307-315. PubMed ID: 30738764
[TBL] [Abstract][Full Text] [Related]
11. Serum apolipoprotein A2 isoforms in autoimmune pancreatitis.
Kobayashi T; Sato Y; Nishiumi S; Yagi Y; Sakai A; Shiomi H; Masuda A; Okaya S; Kutsumi H; Yoshida M; Honda K
Biochem Biophys Res Commun; 2018 Mar; 497(3):903-907. PubMed ID: 29481802
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery.
Li S; Xu H; Wu C; Wang W; Jin W; Gao H; Li H; Zhang S; Xu J; Zhang W; Xu S; Li T; Ni Q; Yu X; Liu L
Cancer Med; 2019 Feb; 8(2):572-584. PubMed ID: 30632317
[TBL] [Abstract][Full Text] [Related]
13. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma.
Wang X; Li Y; Tian H; Qi J; Li M; Fu C; Wu F; Wang Y; Cheng D; Zhao W; Zhang C; Wang T; Rao J; Zhang W
BMC Cancer; 2014 Aug; 14():578. PubMed ID: 25106741
[TBL] [Abstract][Full Text] [Related]
14. Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population.
Parikh DA; Durbin-Johnson B; Urayama S
J Gastrointest Cancer; 2014 Mar; 45(1):74-9. PubMed ID: 24272911
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma.
Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Arigami T; Mori S; Ueno S; Shinchi H; Takao S; Natsugoe S
Pancreatology; 2016; 16(6):1051-1056. PubMed ID: 27693096
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance and predictors of complete or near-complete histological response to preoperative chemoradiotherapy in patients with localized pancreatic ductal adenocarcinoma.
Murata Y; Mizuno S; Kishiwada M; Uchida K; Noguchi D; Gyoten K; Hayasaki A; Fujii T; Iizawa Y; Tanemura A; Kuriyama N; Sakurai H; Isaji S
Pancreatology; 2021 Dec; 21(8):1482-1490. PubMed ID: 34452821
[TBL] [Abstract][Full Text] [Related]
17. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
18. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
[TBL] [Abstract][Full Text] [Related]
19. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers.
Kim J; Bamlet WR; Oberg AL; Chaffee KG; Donahue G; Cao XJ; Chari S; Garcia BA; Petersen GM; Zaret KS
Sci Transl Med; 2017 Jul; 9(398):. PubMed ID: 28701476
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive risk stratification of intraductal papillary mucinous neoplasia with malignant potential by serum apolipoprotein-A2-isoforms.
Felix K; Honda K; Nagashima K; Kashiro A; Takeuchi K; Kobayashi T; Hinterkopf S; Gaida MM; Dang H; Brindl N; Kaiser J; Büchler MW; Strobel O
Int J Cancer; 2022 Mar; 150(5):881-894. PubMed ID: 34778955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
